How should hypertension be managed in a woman in her third trimester of pregnancy?

Management of Hypertensive Pregnant Woman in Third Trimester

For a hypertensive pregnant woman in her third trimester, initiate or continue extended-release nifedipine as first-line therapy, with labetalol as an alternative or add-on agent if blood pressure remains uncontrolled, and treat immediately if BP ≥160/110 mmHg. 1

Blood Pressure Thresholds and Treatment Initiation

The management approach depends on the severity and type of hypertension:

• Severe hypertension (BP ≥160/110 mmHg): Requires immediate pharmacologic treatment if sustained for >15 minutes 2
• Non-severe hypertension (BP 140-159/90-109 mmHg): Treatment is indicated for gestational hypertension or preeclampsia; chronic hypertension may be treated at slightly higher thresholds (≥150/95 mmHg in some guidelines) 3

The most recent 2025 guidelines emphasize that BP ≥160/110 mmHg represents a hypertensive emergency in pregnancy, associated with stroke and pulmonary edema risk 1, 2.

First-Line Pharmacologic Agents

Extended-release nifedipine and labetalol are the two first-line antihypertensive medications with the most robust safety data in pregnancy 1:

Nifedipine (Preferred Initial Choice)

• Use extended-release formulation for maintenance therapy
• Advantages: Once-daily dosing improves adherence 1
• More effective at lowering BP than labetalol, resulting in fewer readmissions 4
• Switch to labetalol if patient experiences headaches, tachycardia, or edema as side effects 1

Labetalol (Alternative or Add-On)

• Can be used alone or combined with nifedipine for uncontrolled BP 1
• Contraindicated in reactive airway disease 1
• May require TID or QID dosing due to accelerated drug metabolism in pregnancy 1
• Minimal risks (potential fetal growth restriction, bradycardia, hypoglycemia) with no teratogenicity 1

Methyldopa (Third Option)

• Only medication with long-term infant outcome data 1
• Less effective than beta-blockers and calcium channel blockers for preventing severe hypertension 1
• Should NOT be used for urgent BP reduction 2
• Fallen out of favor in high-income countries but remains common in low-resource settings 1

Critical Contraindications

Absolutely avoid these medications in pregnancy:

• ACE inhibitors
• Angiotensin II receptor blockers (ARBs)
• Mineralocorticoid receptor antagonists
• Direct renin inhibitors

These agents cause fetal teratogenicity and oligohydramnios 1, 5. This contraindication applies even in the first trimester 5.

Management of Severe Hypertension/Hypertensive Emergency

For BP ≥160/110 mmHg sustained >15 minutes 2:

1. Immediate treatment with:

   • IV labetalol, OR
   • Oral nifedipine (short-acting formulation acceptable for acute management) 2

2. Hospitalization is mandatory if proteinuria is present 5

3. Do NOT give magnesium sulfate concomitantly with calcium channel blockers due to risk of severe hypotension from synergism 2

4. Consider delivery if BP remains uncontrolled despite multiple agents, as persistent severe hypertension (≥200/105 mmHg) can lead to stroke 6

Special Considerations for Third Trimester

Monitoring and Surveillance

• Close maternal and fetal surveillance required 7
• Monitor for early warning signs: SBP >160 mmHg, tachycardia, oliguria 2
• Assess for proteinuria periodically to screen for preeclampsia 2
• All preeclamptic women should be hospitalized in centers with adequate maternal and neonatal intensive care 2

Delivery Timing

• Induction of labor should occur after 37 weeks gestation for preeclampsia 2
• Emergency delivery may be necessary if BP remains uncontrolled despite aggressive treatment (as demonstrated in case reports of stroke at 31 weeks) 6

Blood Pressure Goals

A critical nuance: Avoid excessive BP lowering. Recent evidence from the CHAP trial shows that low BP (systolic <110 mmHg, diastolic <70 mmHg, or MAP <80 mmHg) in the third trimester does NOT increase risk of small-for-gestational-age infants 8. However, the goal remains BP <140/90 mmHg rather than more aggressive targets, as lower targets risk poor placental perfusion 9.

Common Pitfalls to Avoid

1. Using methyldopa for acute BP control - it is ineffective for urgent reduction 2
2. Combining magnesium sulfate with calcium channel blockers - risk of severe hypotension 2
3. Continuing ACE inhibitors/ARBs - must be stopped immediately if pregnancy discovered 1
4. Delaying treatment of severe hypertension - BP ≥160/110 mmHg for >15 minutes requires immediate action 2
5. Inadequate postpartum follow-up - 10% of maternal deaths from hypertensive disorders occur postpartum 2

Postpartum Considerations

• BP may remain elevated for up to 12 weeks postpartum 1
• 40% have BP ≥140/90 mmHg at 16 days postpartum 1
• Nifedipine, labetalol, enalapril, and metoprolol are safe for breastfeeding 2
• Annual BP monitoring required lifelong due to increased cardiovascular disease risk 1, 7, 9